A Double-blind, randomized, placebo-controlled multi-center, Phase II parallel dose-ranging study to assess the antifibrotic activity of G1262570 in chronic hepatitis C subjects with hepatic fibrosis (2006–2007)
- Grant type:
- Glaxo Smith Kline Aust. Pty Ltd
- Researchers:
-
-
- Funded by:
- GlaxoSmithKline Australia Pty Ltd
